Premier Biomedical Inc
Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors… Read more
Premier Biomedical Inc (BIEI) - Net Assets
Latest net assets as of March 2025: $-2.55 Million USD
Based on the latest financial reports, Premier Biomedical Inc (BIEI) has net assets worth $-2.55 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.55K) and total liabilities ($2.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.55 Million |
| % of Total Assets | -72005.05% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 243.76 |
Premier Biomedical Inc - Net Assets Trend (2010–2024)
This chart illustrates how Premier Biomedical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Premier Biomedical Inc (2010–2024)
The table below shows the annual net assets of Premier Biomedical Inc from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.58 Million | -3.98% |
| 2023-12-31 | $-2.48 Million | -8.87% |
| 2022-12-31 | $-2.28 Million | -1.38% |
| 2021-12-31 | $-2.25 Million | -1.52% |
| 2020-12-31 | $-2.22 Million | -20.86% |
| 2019-12-31 | $-1.83 Million | +14.65% |
| 2018-12-31 | $-2.15 Million | +17.75% |
| 2017-12-31 | $-2.61 Million | -295.14% |
| 2016-12-31 | $-660.70K | -55.26% |
| 2015-12-31 | $-425.56K | -528.05% |
| 2014-12-31 | $-67.76K | +72.79% |
| 2013-12-31 | $-249.01K | -228.66% |
| 2012-12-31 | $-75.77K | -350.68% |
| 2011-12-31 | $30.22K | +136.85% |
| 2010-12-31 | $12.76K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Premier Biomedical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1795173000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | % |
| Other Components | $15.36 Million | % |
| Total Equity | $-2.58 Million | 100.00% |
Premier Biomedical Inc Competitors by Market Cap
The table below lists competitors of Premier Biomedical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cartica Acquisition Corp Warrant
NASDAQ:CITEW
|
$586.20K |
|
Sylla Gold Corp.
PINK:SYGCF
|
$586.29K |
|
Joshua Gold Resources Inc
PINK:JSHG
|
$586.43K |
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
$586.68K |
|
Fbec Worldwide
PINK:FBEC
|
$585.64K |
|
Colibri Resource Corporation
PINK:CRUCF
|
$585.48K |
|
NuGene International Inc
PINK:NUGN
|
$585.17K |
|
Cyon Exploration Ltd
PINK:CYNXF
|
$584.42K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Premier Biomedical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,482,073 to -2,580,914, a change of -98,841.
- Net loss of 98,841 reduced equity.
- Other comprehensive income increased equity by 10,988.
- Other factors decreased equity by 10,988.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-98.84K | -3.83% |
| Other Comprehensive Income | $10.99K | +0.43% |
| Other Changes | $-10.99K | -0.43% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Premier Biomedical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $0.32 | $0.00 | x |
| 2011-12-31 | $0.67 | $0.00 | x |
| 2012-12-31 | $-1.61 | $0.00 | x |
| 2013-12-31 | $-3.93 | $0.00 | x |
| 2014-12-31 | $-0.83 | $0.00 | x |
| 2015-12-31 | $-3.40 | $0.00 | x |
| 2016-12-31 | $-272.34 | $0.00 | x |
| 2017-12-31 | $-1.33 | $0.00 | x |
| 2018-12-31 | $-0.61 | $0.00 | x |
| 2019-12-31 | $-0.03 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
| 2024-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Premier Biomedical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-25.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -16.90% | 0.00% | 0.00x | 1.19x | $-3.43K |
| 2011 | -370.11% | 0.00% | 0.00x | 1.10x | $-114.88K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.71 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.85 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.40 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.54 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.70 Million |
| 2017 | 0.00% | -9466.56% | 0.19x | 0.00x | $-3.50 Million |
| 2018 | 0.00% | -1002.64% | 0.24x | 0.00x | $-184.26K |
| 2019 | 0.00% | -2618.86% | 0.14x | 0.00x | $-190.72K |
| 2020 | 0.00% | -39603.83% | 0.22x | 0.00x | $-181.65K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $186.12K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $178.73K |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $46.21K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $159.25K |
Industry Comparison
This section compares Premier Biomedical Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Premier Biomedical Inc (BIEI) | $-2.55 Million | -16.90% | N/A | $585.78K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |